EP0946180A4 - Methoden zur stimulierung der knochenbildung - Google Patents

Methoden zur stimulierung der knochenbildung

Info

Publication number
EP0946180A4
EP0946180A4 EP97945563A EP97945563A EP0946180A4 EP 0946180 A4 EP0946180 A4 EP 0946180A4 EP 97945563 A EP97945563 A EP 97945563A EP 97945563 A EP97945563 A EP 97945563A EP 0946180 A4 EP0946180 A4 EP 0946180A4
Authority
EP
European Patent Office
Prior art keywords
bone formation
stimulating bone
stimulating
formation
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97945563A
Other languages
English (en)
French (fr)
Other versions
EP0946180A1 (de
Inventor
Fred H Drake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0946180A1 publication Critical patent/EP0946180A1/de
Publication of EP0946180A4 publication Critical patent/EP0946180A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97945563A 1996-10-07 1997-10-07 Methoden zur stimulierung der knochenbildung Withdrawn EP0946180A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2776496P 1996-10-07 1996-10-07
US27764P 1996-10-07
PCT/US1997/018178 WO1998015278A1 (en) 1996-10-07 1997-10-07 Method for stimulating bone formation

Publications (2)

Publication Number Publication Date
EP0946180A1 EP0946180A1 (de) 1999-10-06
EP0946180A4 true EP0946180A4 (de) 2003-07-23

Family

ID=21839659

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97945563A Withdrawn EP0946180A4 (de) 1996-10-07 1997-10-07 Methoden zur stimulierung der knochenbildung

Country Status (3)

Country Link
EP (1) EP0946180A4 (de)
JP (1) JP2001501951A (de)
WO (1) WO1998015278A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds
US6008213A (en) * 1995-06-29 1999-12-28 Smithkline Beecham Corporation Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
HUP0003949A2 (hu) * 1997-09-24 2001-10-28 Smithkline Beecham Corp. Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények
UA71586C2 (en) * 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
AUPP794898A0 (en) * 1998-12-24 1999-01-28 Garvan Institute Of Medical Research Transgenic animal
CA2358855A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
CN1374863A (zh) 1999-07-21 2002-10-16 惠氏公司 αvβ3整联蛋白的双环选择性拮抗剂
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
WO2003059880A1 (fr) 2002-01-11 2003-07-24 Sankyo Company, Limited Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
CA2557536C (en) 2004-02-24 2010-07-13 Sankyo Company Limited Amino alcohol compound
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
US20100069302A1 (en) 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
EP2445534A2 (de) 2009-05-25 2012-05-02 Merck Patent GmbH Kontinuierliche verabreichung von cilengitid in der krebstherapie
EP2878339A1 (de) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3-Antagonisten
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
CN103772273A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-氯吡啶的合成方法
CN103880739A (zh) * 2014-03-12 2014-06-25 定陶县友帮化工有限公司 一种2-boc-氨基-3-羟基吡啶的合成方法
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169837A (en) * 1991-03-28 1992-12-08 Allelix Biopharmaceuticals Inc. Isolated osteogenic factor
EP0528587A1 (de) * 1991-08-09 1993-02-24 Merck & Co. Inc. Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
EP0557663A1 (de) * 1992-02-27 1993-09-01 Delmas, Pierre, Dr. Einschätzung der Beinzerbrechlichkeit und Voraussage osteoporotischer Bruchaussicht unter Verwendung einer quantitativen Bestimmung zirkulierendes unterkarboxyliertes Osteokalzin
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812119A (en) * 1969-11-21 1974-05-21 Ciba Geigy Corp Dibenzocycloheptenes
US5686116A (en) * 1990-01-12 1997-11-11 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of enhancing repair, healing and augmentation of bone implants
JP2935541B2 (ja) * 1990-06-28 1999-08-16 サントリー株式会社 縮合複素環化合物
JPH0792165A (ja) * 1993-09-21 1995-04-07 Hoechst Japan Ltd 骨粗鬆症診断剤
MX9700041A (es) * 1994-06-29 1997-04-30 Smithkline Beecham Corp Antagonistas de receptor de vitronectina.
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169837A (en) * 1991-03-28 1992-12-08 Allelix Biopharmaceuticals Inc. Isolated osteogenic factor
EP0528587A1 (de) * 1991-08-09 1993-02-24 Merck & Co. Inc. Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten
EP0557663A1 (de) * 1992-02-27 1993-09-01 Delmas, Pierre, Dr. Einschätzung der Beinzerbrechlichkeit und Voraussage osteoporotischer Bruchaussicht unter Verwendung einer quantitativen Bestimmung zirkulierendes unterkarboxyliertes Osteokalzin
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9815278A1 *

Also Published As

Publication number Publication date
WO1998015278A1 (en) 1998-04-16
JP2001501951A (ja) 2001-02-13
EP0946180A1 (de) 1999-10-06

Similar Documents

Publication Publication Date Title
EP0946180A4 (de) Methoden zur stimulierung der knochenbildung
IL126203A0 (en) Method for treating pain
EP0906104A4 (de) Schmerzbehandlungsverfahren
HU9700851D0 (en) Method for producing l-lysin
AU9035498A (en) Method for treating pain
GB2319796B (en) Formation treatment method using deformable particles
IL118196A0 (en) Methods for inhibiting bone loss
GB9617780D0 (en) Method of treatment
IL127620A0 (en) Method for producing therapeutic DNA
HUP0000456A3 (en) Method for preparing cyclopropylamines
IL126064A0 (en) Method for treating pain
GB9605828D0 (en) Treatment method
HUP0000554A3 (en) Method for producing n-substituted 3-hydroxipyrazoles
HUP9802589A3 (en) Bone stimulating factor
IL124786A0 (en) Method for treating pain
GB2359316B (en) Formation treatment method using deformable particles
AU2810497A (en) Methods for inducing bone formation
AU9034798A (en) Method for treating pain
GB9714841D0 (en) Treatment method
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
ZA968062B (en) Bone stimulating factor
IL130092A0 (en) Method for producing 2-chloro-5-aminomethylthiazole from 2-chloro-5-methylthiazole via 2-chloro-5-chloromethylthiazole
GB9604739D0 (en) Surgical method
GB9824573D0 (en) Methods for stimulating bone formation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20030605

17Q First examination report despatched

Effective date: 20030901

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040113

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023061

Country of ref document: HK